What is Claimed is:

1. A composition comprising a pharmaceutically acceptable cyclobenzaprine salt and a basifying agent, characterized in that, when the composition is administered by transmucosal absorption, the composition is characterized in that it affords one or more of a dnC* of cyclobenzaprine of: greater than or equal to 0.1 ± 25% x 10^{-7} mL^{-1} 15 minutes after administration; greater than or equal to 0.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 1.5 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; greater than or equal to 4.0 ± 25% x 10^{-7} mL^{-1} 1 hour after administration; greater than or equal to 5.2 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 9.0 ± 25% x 10^{-6} mL^{-1} 3 hours after administration; or less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 10 hours, 12 hours, 14, hours, 16 hours or 18 hours after administration.

2. The composition of claim 1, wherein the transmucosal absorption is sublingual absorption.

3. The composition of claim 1 or 2, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.

4. The composition of any one of claims 1 to 3, wherein the composition is characterized in that it affords one or more of a dnC* of cyclobenzaprine of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration; greater than or equal to 157.60 x 10^{-9} mL^{-1} 20 minutes after administration; greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; 4.2 ± 25% x 10^{-7} mL^{-1} 60 minutes after administration; greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration; or greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

5. The composition of any one of claims 1 to 4, wherein the composition is characterized in that it affords one or more of a $dnAUC_{0\text{-}20min}$ of cyclobenzaprine of greater than or equal to 0.02

± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}30min}$ of greater than or equal to 0.05 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}45min}$ of greater than or equal to 0.14 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}1h}$ of greater than or equal to 0.26 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}2h}$ of greater than or equal to 0.87 ± 25% x 10^{-6} hr mL^{-1}, or a $dnAUC_{0\text{-}2.5h}$ of greater than or equal to 1.23 ± 25% x 10^{-6} hr mL^{-1}.

6. The composition of any one of claims 1 to 5, wherein the composition is characterized in that it affords a $dnAUC_{0\text{-}\infty h}$ of cyclobenzaprine of greater than or equal to 20 hr mL^{-1}.

7. The composition of any one of claims 1 to 6, wherein the composition is characterized in that it affords a dnC_{max}* of cyclobenzaprine of greater than or equal to 1.0 ± 25% x 10^{-6} mL^{-1}.

8. The composition of any one of claims 1 to 7, wherein the composition is characterized in that it affords a plasma concentration of cyclobenzaprine of 50% or less of the C_{max} at one or more of 4 hours, 6 hours, 8 hours or 12 hours after administration.

9. The composition of any one of claims 1 to 8, wherein the composition is characterized in that it affords a C_{max} of cyclobenzaprine of greater than or equal to 2 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, or 30 ng/mL.

10. The composition of any one of claims 1 to 9, wherein the composition is characterized in that it affords a t_{max} of cyclobenzaprine of less than 4 hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, or less than 15 minutes.

11. The composition of any one of claims 1 to 3, wherein the composition comprises 2 mg to 20 mg of a pharmaceutically acceptable cyclobenzaprine salt, and is characterized in that, said composition affords a C_{max} of cyclobenzaprine from 20 ng/mL to 200 ng/mL from 0.05 hours to 2.5 hours after administration for four days or more daily, and a minimum cyclobenzaprine plasma concentration from 1 ng/mL to 5 ng/mL from 22 hours to 26 hours after administration.

12. Use of a composition according to any one of claims 1 to 11 in the manufacture of a medicament formulated for transmucosal absorption for treating a disease or condition in an individual, wherein the disease or condition is selected from the group consisting of post-traumatic stress disorder (PTSD), fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, and anxiety disorder.

13. The use according to claim 12, wherein the transmucosal absorption is sublingual absorption, optionally wherein the medicament is selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

14. The use according to claim 12 or 13, wherein the disease or condition is post-traumatic stress disorder (PTSD).

15. The use according to claim 12 or 13, wherein the disease or condition is selected from the group consisting of fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, and anxiety disorder.

16. The use according to any one of claims 12 to 15, wherein the medicament is characterized in that it affords one or more of a dnC* of cyclobenzaprine of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration; greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; greater than or equal to 4.2 ± 25% x 10^{-7} mL^{-1} 1 hour after administration; greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration; greater than or equal to 8.0 ± 25% x 10^{-7} mL^{-1} 3.3 hours after administration; or less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 12 hours, 14 hours, 16 hours or 18 hours after administration.

17. The use according to any one of claims 12 to 16, wherein the medicament is characterized in hat it affords one or more of a dnC* of cyclobenzaprine of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration; greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; greater than or equal to 4.2 ± 25% x 10^{-7} mL^{-1} 1 hour after administration; greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration; greater than or equal to 727.67 ± 25% x 10^{-9} mL^{-1} 2.5 hours after administration; or greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

18. Use of a composition according to any one of claims 1 to 3 in the manufacture of a medicament formulated for transmucosal administration for treating fibromyalgia or reducing the symptoms of fibromyalgia in a human patient, the medicament comprising from 2 mg to 20 mg

of a pharmaceutically acceptable cyclobenzaprine salt, where the medicament is characterized in that, when the medicament is administered by transmucosal absorption for four days or more daily within two hours of sleep, said medicament affords a C_{max} of cyclobenzaprine from 20 ng/mL to 200 ng/mL from 0.05 hours to 2.5 hours after administration, and a minimum plasma concentration from 1 ng/mL to 5 ng/mL from 22 hours to 26 hours after administration.